Netherlands Cancer Institute to develop next generation cancer treatment in new partnership
Building on its long history of innovation, the Amsterdam-based Netherlands Cancer Institute (NKI) is teaming up with Swedish radiotherapy firm Elekta to develop the next generation of treatment for cancer patients.
Netherlands Cancer Institute to co-develop innovative cancer care
The Netherlands Cancer Institute (NKI) is partnering with radiotherapy provider Elekta to bring cutting-edge cancer treatment to patients and develop next generation solutions.
The Amsterdam hospital, known to be among the world’s best comprehensive cancer centres, will combine resources, knowledge and expertise with Swedish firm Elekta, a leader in precision radiotherapy, in a ten-year strategic partnership.
The collaboration aims to accelerate improvements in Elekta in imaging, personalised and adaptive radiotherapy products, artificial intelligence (AI), and software solutions for improved workflows and decision-making support. Teams will also research and develop solutions for personalised treatment management software.
Mutual innovative force
Anke van Mourik, head of medical physics radiotherapy at NKI, said: “The strength of this collaboration is the synergy in visions, the mutual innovative force and the close collaboration between research and the clinic. I am convinced that with our Elekta fleet and joint innovations, we can make a true impact on patient care.”
Jan Jakob Sonke, professor of adaptive radiotherapy, added: “I am excited to build on our long history of collaboration, innovation and state-of-the-art solutions with Elekta. Together we can make a big step forward in personalised radiotherapy and provide the best possible outcomes for every patient.”
A cornerstone of Amsterdam's life sciences ecosystem
The NKI forms a cornerstone of the life sciences and health community in Amsterdam. The concentration of many research institutions, hospitals and universities in the Dutch capital form an innovative life sciences and health ecosystem that thrives on knowledge-sharing and collaborations. Startups and corporations are also galvanised by the presence of the European Medicines Agency (EMA), which moved to Amsterdam in 2019. Research last year found ground-breaking developments from Amsterdam's life sciences and health sector have the third highest impact in the world.
